Study Links GLP-1 Drugs to Increased Risk of Bone Health Issues
Recent research presented at the 2026 American Academy of Orthopaedic Surgeons annual meeting has raised concerns about the potential side effects of GLP-1 agonist drugs, commonly used to treat obesity and type 2 diabetes. The study, which has not yet been peer-reviewed, suggests a correlation between the use of these medications and an increased risk of bone-related issues such as osteoporosis and osteomalacia. Additionally, the study found a link between GLP-1 use and a heightened risk of gout, a form of arthritis. The research analyzed five years of medical records from nearly 147,000 adults with type 2 diabetes and obesity, concluding that GLP-1 use was associated with a significantly increased risk of these conditions. Despite these findings, experts caution that the study is observational and does not establish a direct causal relationship between GLP-1 drugs and bone health issues. 
